Posaconazole

Drug Profile

Posaconazole

Alternative Names: IV posaconazole; MK-5592; Noxafil; Posaconazole oral suspension; Posaconazole SP; Posaconazole tablet; Posanol; SCH 056592; SCH 56592; Spriafil

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Schering-Plough
  • Developer Merck & Co; MSD China; Schering-Plough
  • Class Antifungals; Triazoles
  • Mechanism of Action 14-alpha demethylase inhibitors; Cytochrome P 450 enzyme system inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Aspergillosis
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Aspergillosis; Candidiasis; Mycoses; Oropharyngeal candidiasis
  • Phase II Chagas disease

Most Recent Events

  • 08 Nov 2017 Merck Sharp & Dohme plans a phase I trial in Mycoses (MK-5592-120; NCT03336502)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Mycoses(In adolescents, In children, In infants) in Canada (PO, Suspension)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Mycoses(In adolescents, In children, In infants) in Greece (PO, Suspension)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top